Alexander Goetsch

Apr 11, 2023 | tandfonline.com | Alessandra Zilli |Tommaso Lorenzo Parigi |Laurent Peyrin-Biroulet |Alexander Goetsch

AbstractIntroduction Janus kinase (JAK) inhibitors are an emerging class of small-molecule drugs, providing targeted therapy for a variety of diseases, and have made their way into the treatment armamentarium of ulcerative colitis (UC) in recent years. Areas covered This review focuses on the pharmacokinetics, safety, and efficacy of selective JAK1 inhibitors in the treatment of moderate to severe UC.